SPH17 Antibody

What is Sp17 and why is it significant in biomedical research?

Sp17 is a highly conserved mammalian protein initially identified as a testis-specific protein expressed at high levels during the sperm acrosome reaction. Despite early classification as testis-specific, research has demonstrated Sp17 expression across multiple tissues including adrenal glands, lymph nodes, skeletal muscle, spine, ovary, parathyroid gland, and synovium . Sp17 has gained significant research attention due to its aberrant expression in multiple cancer types and its potential as both a diagnostic biomarker and therapeutic target .

The protein is particularly noteworthy for being highly immunogenic, with anti-Sp17 autoantibodies detected in various clinical contexts including vasectomized men and patients with periampullary carcinoma . This immunogenicity makes Sp17 an attractive candidate for vaccine development, particularly in cancers where it shows high expression levels.

How is Sp17 expression detected in experimental settings?

Researchers employ multiple complementary techniques to detect Sp17 expression:

• mRNA detection: RT-PCR has been used to validate the distribution of Sp17 isoforms in various tissues, detecting specific variants like Sp17-1a and Sp17-1b mRNAs in different tissue types .

• Protein detection: Immunohistochemistry (IHC) is commonly used to assess Sp17 protein expression in tissue samples, with patterns varying from cytoplasmic localization to nuclear staining. For example, in DLBCL (Diffuse Large B-Cell Lymphoma) patients, Sp17 staining patterns range from cytoplasmic distribution to scattered nuclear expression in 5-10% of cells .

• Autoantibody detection: ELISA and western blot assays are effective for measuring anti-Sp17 autoantibody levels in serum samples, as demonstrated in studies of SAPHO syndrome patients .

Standardization of detection methods remains an active area of research, as sensitivity and specificity requirements may vary depending on the clinical or research context.

What is the relationship between Sp17 expression and immune system function?

Sp17 demonstrates significant interactions with the immune system that make it particularly relevant for immunotherapy research. Studies indicate that Sp17 expression correlates significantly with immune-activated hallmarks, including specific pathways and biological processes . Additionally, Sp17 expression levels show correlation with immune cell infiltrations in tumor microenvironments and with immunoregulator expressions .

Perhaps most significantly from a clinical perspective, Sp17 expression has been shown to predict responses to immune checkpoint inhibitor therapy. Research indicates that Sp17 expression can significantly predict anti-PDL1 and anti-PD1 therapy responses in cancer patients . This relationship positions Sp17 as not only a biomarker but potentially as a predictive indicator that could guide immunotherapy decisions in precision oncology applications.

How effective is serum Sp17 autoantibody as a diagnostic biomarker for SAPHO syndrome?

Serum anti-Sp17 autoantibody has been identified as a potential specific biomarker for SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome, which currently lacks specific diagnostic markers. Research has shown significantly increased levels of anti-Sp17 autoantibody in patients with active SAPHO compared to both patients with inactive disease and healthy controls (P < 0.05) .

The specificity of anti-Sp17 autoantibody for SAPHO syndrome is particularly notable. While inflammatory markers like hsCRP and ESR are elevated in many inflammatory and immunological disorders, elevated serum levels of anti-Sp17 autoantibodies appear to be more specific to SAPHO syndrome . This specificity potentially makes it superior to conventional inflammatory markers for both diagnosis and disease monitoring.

Importantly, the biomarker shows correlation with disease activity. In patients with active SAPHO, serum Sp17 autoantibody levels correlate significantly with:

• Hypersensitive C-reactive protein (hsCRP)

• Erythrocyte sedimentation rate (ESR)

• β-crosslaps (β-CTx)

This correlation with established inflammatory indices suggests that Sp17 autoantibody levels reliably reflect disease activity, particularly systemic inflammation status in SAPHO patients.

Can Sp17 expression predict prognosis in cancer patients?

Research indicates that Sp17 has significant prognostic value across multiple cancer types. Studies have shown that Sp17 is aberrantly expressed in most cancer types and demonstrates prognosis predictive ability in various cancers . The relationship between Sp17 expression and clinical outcomes appears to be consistent across different malignancies, suggesting a fundamental biological role in cancer progression.

Beyond mere correlation with outcomes, Sp17 expression also appears to be mechanistically linked to cancer biology through its association with:

• Immune cell infiltration in tumor microenvironments

• Expression of immunoregulatory molecules

• Activation of specific immune-related pathways and biological processes

These mechanistic connections strengthen the case for Sp17 as not merely a correlative marker but as a biologically relevant factor in cancer progression and response to therapy.

How does Sp17 autoantibody relate to bone metabolism markers in SAPHO patients?

Research has revealed a significant positive correlation between serum Sp17 autoantibody levels and bone metabolism markers in patients with active SAPHO syndrome. Specifically, Sp17 autoantibody levels show positive correlation with:

• Osteocalcin: A bone-specific calcium-binding protein released during bone formation and resorption by osteoblasts

• β-CTx (β-crosslaps): The main fragment of type I collagen degradation by osteoclasts, indicating osteolysis and strong bone resorption

These correlations suggest that Sp17 autoantibody levels are associated with osteoarthritis and osteolytic lesions, which are key manifestations of SAPHO syndrome. This relationship provides valuable insights into the potential role of Sp17 in bone metabolism dysregulation and offers an additional dimension to its utility as a disease marker in rheumatological conditions .

How is Sp17 being developed as a cancer vaccine target?

Sp17 represents a promising cancer vaccine candidate, particularly for ovarian cancer where it is expressed in primary and metastatic lesions in >83% of patients . Vaccine development efforts have focused on several innovative approaches:

• Nanoparticle-based delivery systems: Researchers have developed nanoparticle-based vaccines using human Sp17 (hSp17) sequence-derived peptides. This approach has successfully identified immunodominant T cell and antibody epitopes, with the primary T and B cell immunodominant region mapping to amino acids 111-142 .

• Epitope optimization: Research has shown that delivery method influences the specificity of immune responses, with nanoparticle conjugation changing the dominant antibody isotype from IgG2a to IgG1 and altering the fine specificity of B cell epitopes within hSp17 111-142 .

• Cross-reactivity enhancement: Notably, conjugation of Sp17 peptides to nanoparticles substantially increased antibody cross-reactivity between mouse and human Sp17, demonstrating that delivery systems can be engineered to enhance desired immune response characteristics .

The development of Sp17-targeted vaccines represents an intersection of cancer immunotherapy and nanotechnology, with ongoing research focused on optimizing delivery platforms, epitope selection, and immune response profiling.

What is the evidence for Sp17 as an immunotherapy target in lymphoma?

Research has demonstrated that Sp17 represents a potential immunotherapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL). Studies have documented both cytotoxic T lymphocyte (CTL) and CD4 T helper cell responses to Sp17 in DLBCL patients .

The evidence for Sp17 as a viable immunotherapy target in DLBCL includes:

• HLA association: Studies have identified HLA-A*0201-restricted immune responses to Sp17-derived peptides in DLBCL patients, with significant γ-IFN responses detected in patient samples .

• Expression patterns: Immunohistochemical analysis has revealed variable Sp17 expression patterns in DLBCL tissues, ranging from cytoplasmic staining to nuclear localization in a subset of cells. This expression provides the antigenic basis for immune targeting .

• Immune response profiling: As shown in Table 1 from the provided research, multiple DLBCL patients demonstrated significant γ-IFN responses to Sp17 peptides, with response magnitudes ranging from 48±4 to 102±16 per 50,000 cells for certain peptide sequences .

This combination of expression patterns and documented immune responses supports further investigation of Sp17-targeted immunotherapeutic approaches for DLBCL.

How can Sp17-specific inhibitors be identified for therapeutic development?

The identification of Sp17-specific inhibitors represents an emerging area of research with significant therapeutic potential. One methodological approach to identify potential inhibitors has involved analysis of drug sensitivity information from the Connectivity Map (CMap) dataset .

This computational drug repurposing strategy has yielded promising candidates that correlate with Sp17 expression in different cancer types, including:

• Irinotecan: A topoisomerase inhibitor that shows correlation with Sp17 expression patterns

• Puromycin: An aminonucleoside antibiotic that demonstrates specificity related to Sp17 expression

The methodology for identifying such inhibitors typically involves:

• Expression correlation analysis: Examining the relationship between Sp17 expression levels and drug sensitivity profiles across cancer cell lines

• Pathway-based screening: Identifying compounds that target pathways associated with Sp17 expression or function

• Functional validation: Testing candidate compounds in cellular and animal models to confirm specific activity against Sp17-expressing cells

This drug discovery approach complements immunotherapeutic strategies and may lead to combination therapies that simultaneously target Sp17 through multiple mechanisms.

What are optimal approaches for designing nanoparticle-based Sp17 vaccines?

The design of nanoparticle-based Sp17 vaccines requires careful consideration of multiple parameters to optimize immunogenicity and therapeutic efficacy. Based on current research, several methodological approaches have proven effective:

• Structural scaffold selection: Studies have demonstrated success using hepatitis B virus (HBV) capsid as a nanoparticle scaffold, which assembles as dimers to form spikes. This scaffold comprises 240 monomeric units that assemble into an icosahedral capsid approximately 30 nm in diameter .

• Epitope integration strategy: An effective design approach involves integrating tandem copies of antigenic peptides into each monomeric unit of the nanoparticle scaffold. For example, researchers have integrated two tandem copies of helix-A (an antigenic peptide) into each monomeric unit of HBV capsid, resulting in 480 copies of the sequence per nanoparticle .

• Insertion site optimization: Placement of the antigen at the immunodominant loop position (atop a loop positioned on the spike of HBV capsid) has been shown to enhance immunogenicity, as this site is the target of the majority of antibodies elicited by the HBV capsid .

• Fine epitope mapping: When designing Sp17-based vaccines, researchers have identified that the primary T and B cell immunodominant region maps to amino acids 111-142, providing a rational basis for peptide selection .

• Delivery system impact assessment: The choice of delivery system significantly influences immune response characteristics. For instance, nanoparticle conjugation has been shown to shift the dominant antibody isotype from IgG2a to IgG1 and alter the fine specificity of B cell epitopes compared to conventional adjuvant approaches .

These methodological considerations highlight the importance of rational design principles in developing effective nanoparticle-based Sp17 vaccines for cancer immunotherapy.

What methods are most reliable for measuring anti-Sp17 autoantibody levels in clinical samples?

The accurate measurement of anti-Sp17 autoantibody levels in clinical samples is critical for both research applications and potential diagnostic use. Based on current literature, the following methodological approaches have demonstrated reliability:

• Enzyme-Linked Immunosorbent Assay (ELISA): ELISA has been successfully employed to measure anti-Sp17 autoantibody levels in serum samples from patients with SAPHO syndrome. This approach allows for quantitative assessment of antibody levels and correlation with clinical parameters .

• Western Blot Assay: Western blotting provides a complementary approach for confirming the presence of anti-Sp17 autoantibodies, offering information about specificity through molecular weight verification. This method has been used to validate initial findings from protein microarray screening .

• Protein Microarray Screening: High-throughput screening using protein microarrays containing human proteins (such as the 17K human whole-proteome microarray used in SAPHO syndrome research) provides an initial approach for identifying autoantibody targets, though results require validation through more specific methods like ELISA and western blotting .

• Controls and Standards: Methodological reliability is enhanced through appropriate controls, including:

  • Comparison with healthy control samples

  • Inclusion of patients with inactive disease as disease controls

  • Use of recombinant Sp17 protein as a standard

  • Implementation of standardized cutoff values based on reference populations

For clinical applications, a combination of these methods may provide the most robust assessment of anti-Sp17 autoantibody levels, with ELISA serving as the primary quantitative assay and western blotting providing confirmatory specificity data.

How can researchers distinguish between Sp17 isoforms in experimental systems?

Distinguishing between Sp17 isoforms represents an important methodological challenge in research settings, as different isoforms may have distinct functional properties and tissue distributions. Based on available literature, several approaches can be employed:

• Isoform-specific RT-PCR: RT-PCR using primers designed to distinguish between Sp17 isoforms (such as Sp17-1a and Sp17-1b) has been successfully employed to characterize isoform distribution across tissues. This approach has revealed that Sp17-1a mRNA is present in human adrenal glands, lymph nodes, skeletal muscle, spine, ovary, and adult testis, while both Sp17-1a and Sp17-1b mRNAs have been detected in PBMCs, the parathyroid gland, and the synovium .

• Antibodies targeting isoform-specific regions: Development and characterization of antibodies that specifically recognize unique regions of different Sp17 isoforms can enable differential detection in immunohistochemistry, flow cytometry, and western blotting applications.

• Mass spectrometry-based proteomics: This approach allows for precise identification of Sp17 isoforms based on peptide mass fingerprinting and sequence analysis, providing high-resolution discrimination between closely related protein variants.

• Recombinant expression systems: Generation of recombinant isoform standards for assay calibration and validation ensures accurate identification and quantification of specific Sp17 variants in experimental samples.

When designing experiments to distinguish between Sp17 isoforms, researchers should consider the tissue-specific expression patterns documented in previous studies and select appropriate methodological approaches based on the specific research questions being addressed.

How should researchers address conflicting data regarding Sp17's role across different disease contexts?

Researchers investigating Sp17 face the challenge of reconciling sometimes conflicting data across different disease contexts. A systematic approach to addressing these conflicts includes:

• Context-specific analysis: Recognize that Sp17's biological role may genuinely differ between disease contexts. For example, its function as a biomarker in SAPHO syndrome may involve different mechanisms than its role in cancer progression . Design studies that specifically examine context-dependent functions rather than assuming uniform behavior.

• Methodological standardization: Implement consistent methodologies for Sp17 detection and quantification across studies to minimize technical variability as a source of conflicting results. This includes standardized antibodies, detection protocols, and data analysis approaches.

• Isoform-specific investigations: Consider that different Sp17 isoforms may predominate in different disease contexts. Studies should clearly specify which isoforms are being examined and avoid generalizing findings from one isoform to all Sp17 variants .

• Integrated multi-omics approaches: Combine proteomic, transcriptomic, and functional analyses to develop a more comprehensive understanding of Sp17's role in specific contexts, allowing for the integration of seemingly conflicting data points into more nuanced models.

• Collaborative research networks: Establish research consortia focused on Sp17 to facilitate data sharing, protocol standardization, and direct comparison of results across laboratories and disease contexts.

By acknowledging the complex, context-dependent nature of Sp17 biology, researchers can develop more sophisticated experimental designs that account for potential sources of conflicting data.

What are the main technological barriers to advancing Sp17-targeted therapies?

Despite promising research on Sp17 as a therapeutic target, several technological barriers currently limit clinical translation:

• Delivery system optimization: While nanoparticle-based approaches show promise for Sp17-targeted vaccines , optimizing delivery systems for specific tissue targeting, stability, and controlled release remains challenging. Researchers must balance immunogenicity with safety considerations in delivery platform design.

• Epitope heterogeneity: The fine specificity of immune responses to Sp17 can vary with delivery method , creating challenges for predicting and controlling therapeutic outcomes. Standardizing epitope selection and presentation formats requires further technological development.

• Patient stratification tools: Current methods for identifying patients most likely to benefit from Sp17-targeted therapies remain suboptimal. While Sp17 expression correlates with immunotherapy response , more sophisticated biomarker panels and predictive algorithms are needed for reliable patient selection.

• Manufacturing scalability: Translation of laboratory-scale Sp17-targeted therapies (particularly complex nanoparticle formulations) to clinical-grade manufacturing faces technical challenges related to reproducibility, stability, and quality control.

• Combination strategy development: Technologies for rational design of combination therapies integrating Sp17-targeted approaches with existing treatment modalities (such as chemotherapy or other immunotherapies) require further development to maximize therapeutic efficacy.

Addressing these technological barriers will require interdisciplinary collaboration between immunologists, materials scientists, pharmaceutical engineers, and clinicians to develop next-generation Sp17-targeted therapeutic platforms.

How might emerging single-cell technologies advance our understanding of Sp17 biology?

Emerging single-cell technologies offer unprecedented opportunities to resolve current knowledge gaps in Sp17 biology:

• Cellular heterogeneity resolution: Single-cell RNA sequencing (scRNA-seq) can reveal the heterogeneity of Sp17 expression within tumors or inflammatory tissues, potentially identifying specific cell populations where Sp17 plays critical functional roles. This approach could clarify why only subsets of cells (e.g., <10% of nuclei in DLBCL samples ) express Sp17 in some contexts.

• Spatial transcriptomics: These technologies can map Sp17 expression patterns within the tissue microenvironment, providing insights into spatial relationships between Sp17-expressing cells and other cell types, including immune infiltrates. This could advance understanding of how Sp17 expression correlates with immune cell infiltrations in tumor microenvironments .

• Proteomic analysis at single-cell resolution: Emerging technologies for single-cell proteomics could reveal post-translational modifications and protein-protein interactions involving Sp17 that are not detectable in bulk tissue analysis, potentially uncovering new functional roles.

• Immune repertoire analysis: Single-cell immune receptor sequencing could characterize the T and B cell repertoires that respond to Sp17 epitopes, providing insights into the diversity and specificity of anti-Sp17 immune responses relevant to both autoimmunity and cancer immunotherapy.

• Multi-modal data integration: Combining single-cell transcriptomics, proteomics, and functional assays can provide comprehensive views of Sp17 biology that integrate gene expression, protein abundance, and functional consequences at the individual cell level.

These technologies have the potential to transform our understanding of Sp17's biological roles, resolve apparent contradictions in existing data, and identify new therapeutic opportunities based on precise cellular targeting strategies.